AMCP 2020

Presentations

Enfortumab Vedotin | Urothelial Carcinoma | Abstract C32

Real-World Outcomes With Taxane Monotherapy Following Platinum and Anti-Programmed Death 1/Death-Ligand 1 Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Enfortumab Vedotin | Urothelial Carcinoma | Abstract C33

Quality of Life of Metastatic Urothelial Cancer Patients Treated With Enfortumab Vedotin Following Platinum-containing Chemotherapy and a Checkpoint Inhibitor: Data From EV-201 Cohort 1